Alerts will be sent to your verified email
Verify EmailVENMAX
|
Venmax Drugs&Pharma
|
Rekvina Labs
|
Walpar Nutritions
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
1.17 % | 9.93 % | 7.37 % |
|
5yr average Equity Multiplier
|
0.08 | 6.31 | 2.94 |
|
5yr Average Asset Turnover Ratio
|
0.14 | 0.0 | 1.11 |
|
5yr Avg Net Profit Margin
|
-19.62 % | 0.0 | 2.27 % |
|
Price to Book
|
1.63 | 0.0 | 0.0 |
|
P/E
|
94.63 | 0.0 | 11.49 |
|
5yr Avg Cash Conversion Cycle
|
288.55 Days | 0.0 | 51.82 Days |
|
Inventory Days
|
5.2 Days | 0.0 | 101.39 Days |
|
Days Receivable
|
430.69 Days | 0.0 | 88.04 Days |
|
Days Payable
|
141.12 Days | 0.0 | 171.72 Days |
|
5yr Average Interest Coverage Ratio
|
-260.56 | -132.32 | 5.01 |
|
5yr Avg ROCE
|
-47.43 % | -100.9 % | 10.5 % |
|
5yr Avg Operating Profit Margin
|
-65.91 % | 0.0 | 7.34 % |
|
5 yr average Debt to Equity
|
-0.45 | -0.19 | 0.83 |
|
5yr CAGR Net Profit
|
-42.57 % | 18.47 % | 72.93 % |
|
5yr Average Return on Assets
|
199.45 % | -132.46 % | 2.62 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
13.8 % | 41.3 % | 68.82 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-9.33 % | 0.0 | -2.2 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Venmax Drugs&Pharma
|
Rekvina Labs
|
Walpar Nutritions
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|